Skip to main content
Research and analysis

ACRE advice: application for a clinical, vaccine trial of genetically modified Bordetella pertussis (21/R53/01), (22/R53/01) and (26/R59/01)

ACRE's advice on an application for a clinical, vaccine trial of genetically modified Bordetella pertussis.

Documents

ACRE advice: application for a clinical, vaccine trial of genetically modified Bordetella pertussis (21/R53/01), (22/R53/01) and (26/R59/01)

Request an accessible format
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email defra.helpline@defra.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Details

These documents are the advice of the Advisory Committee on Releases to the Environment (ACRE) to government on 3 applications from ILiAD Biotechnologies, Inc and hVIVO Services Ltd to carry out clinical, vaccine trials of genetically modified Bordetella Pertussis.

The committee advised that the risks to human health and the environment from this trial are extremely low.

Sign up for emails or print this page